HOME >> BIOLOGY >> NEWS
Tips from the journals of the American Society for Microbiology

Ulcer Drug Inhibits Gum Disease in Rabbits

Researchers from Boston University School of Medicine have discovered that topical application of an ulcer drug to teeth may help prevent gum disease. Their findings appear in the April 2006 issue of the journal Infection and Immunity.

Periodontitis (gum disease) occurs when the bacterium Porphyromonas gingivalis accumulates on the tooth's surface causing inflammatory disease which leads to loss of connective tissue and bone. This disease affects tens of millions of people in the U.S. alone, emphasizing the importance of effective preventative care and treatment method.

Cimetidine is a powerful H2 receptor antagonist originally designed to treat ulcers by blocking the acid producing cells in the stomach. In the study three groups of rabbits were simultaneously induced with experimental periodontitis using P. gingivalis and treated with varying levels of topically applied cimetidine three times a week over a six-week period. Results showed that topical application of cimetidine at all concentrations inhibited inflammation and bone loss by approximately 90%.

"The findings of this study provide morphological and histological evidence that topically active cimetidine is a potent inhibitor of P. gingivalis-elicited periodontal inflammation, arresting and/or preventing tissue destruction and influencing cell populations present in the inflammatory cell infiltrate," say the researchers.

(H. Hasturk, A. Kantarci, N. Ebrahimi, C. Andry, M. Holick, V.L. Jones, T.E. Van Dyke. 2006. Topical H2 antagonist prevents periodontitis in a rabbit model. Infection and Immunity, 74. 4: 2402-2414.)

Artificial Illumination Using White or Green Light May Prevent Biofilm Formation on Artwork

Using white or green light to artificially illuminate artwork may prevent biofilm formation and surface deterioration, say researchers from Spain. They report their findings in t
'"/>

Contact: Carrie Patterson
cpatterson@asmusa.org
202-942-9389
American Society for Microbiology
14-Apr-2006


Page: 1 2 3

Related biology news :

1. Cluster of journals publish findings on dangerous parasite, Toxoplasma gondii
2. Tips from the journals of the American Society for Microbiology
3. Springer expands life science program with In Vitro journals
4. Tips from the journals of the American Society for Microbiology
5. Tips from the journals of the American Society for Microbiology
6. Impressive new Impact Factors for BioMed Centrals open-access journals
7. Tips from the journals of the American Society for Microbiology
8. Tips from the journals of the American Society for Microbiology
9. Tips from the journals of the American Society for Microbiology
10. Tips from the journals of the American Society for Microbiology
11. Tips from the journals of the American Society for Microbiology

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tips from the journals the American Society for Microbiology

(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: